SHAHEED RAJAIE CARDIOVASCULAR MEDICAL CENTER, VALI-E-ASR AVE., MELLAT PARK, TEHRAN, IRAN
Background: The rapamycin-eluting stent evaluated at RESEARCH registry, reported a 30-day major adverse cardiac event rate of 6.1%. The aim of this study was to evaluate immediate and short-term results (6-9 months) of elective coronary stenting with the non-polymeric rapamycin-eluting Yukon stent in patients with coronary artery disease.
Methods: In this non-randomized cross-sectional study, 96 patients with stable angina and unstable angina with at least one coronary lesion greater than 50% of luminal diameter by angiographic study were investigated. The subjects were treated with aspirin, c1opidogrel and heparin. Stinting was performed in native coronary vessels with all types of lesions; A, Band C. Overall 110 stents were deployed, with 56 stents in LAD and 29 stents in LCX and 25 stents in RCA lesions. Coronary lesions were 16% type A, 43% B1, 25% B2 and 16%type C lesions.
From 96 patients, only 25 patients with 28 stents were re-evaluated 6-9 months after stenting by coronary angiography based on symptom, positive stress test or event. The remaining patients did not refer and refused repeat evaluation due to lack of symptoms. Data were collected in SPSS 10 and analyzed by of T-test, Fisher-exact and Chi squares statistical tests.
Results: 96 patients with mean age of 56 years old, 30% female and 70% male, were studied. Coronary risk factor evaluation in patients showed prevalence of 35% for cigarette smoking, 61% hyperlipidemia, 46% hypertension and 20% diabetes mellitus. 5% of patients had history of CABG surgery and 25% had unstable angina. There was no major cardiac event in the first 48 hours and first 30 days after coronary stenting. In-stent restenosis of greater than 50% in 12% of lesions and in-segment restenosis greater than 50% were seen in 16% of lesions. The most important risk factors for restenosis were diabetes mellitus and stent length.
Conclusion: Results of this study showed acceptable results of coronary stenting with the rapamaycin- eluting stent, Yukon. The most important risk factors for restenosis were diabetes mellitus and stent length.